Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 2018

View Archived Issues

Institut Pasteur de Montevideo and Universidad de la Republica describe new trolox derivatives

MJFF announces funding for investigator-initiated projects in Parkinson's disease

Immunicum obtains ATMP certificate from EMA for ilixadencel

Novel orthoIL-2/IL-2R pairs show efficacy in mouse model of melanoma

FDA expands approval of Adcetris

FDA clears Therapix's IND for phase IIa study of THX-110

Ocugen's phase II study of OCU-310 demonstrates proof-of-concept for dry eye disease

Antibe Therapeutics' ATB-346 shows better gastrointestinal safety in phase IIb study

Intranasal octreotide formulation DP-1038 demonstrates viability in healthy volunteers

KemPharm reports positive topline results from PK study of KP-415

Curtana Pharmaceuticals describes new Oligo2 inhibitors

PR-001, a new 5-HT7 inhibitor for the treatment of inflammatory bowel disease

Novel Bcl-2 inhibitors identified at Centaurus BioPharma

Zealand reports phase III immunogenicity results for dasiglucagon

Shanghai Institute Materia Medica discovers bromodomain-containing protein 4 inhibitors

Biophytis seeks E.U. orphan drug designation for Sarconeos for DMD

Bristol-Myers Squibb discovers novel indoleamine 2,3-dioxygenase 1 inhibitors

Idenix Pharmaceuticals, Merck & Co. patent novel tenofovir prodrugs

Prothena collaborates with Celgene to develop new therapies for neurodegenerative diseases

Helsinn to acquire worldwide rights to Valchlor/Ledaga

ON-150030, a novel therapeutic agent to treat acute myeloid leukemia through FLT3 inhibition

MHRA allows U.K. early access to volanesorsen for familial chylomicronemia syndrome

Arena reports promising topline results from phase II trial of etrasimod in ulcerative colitis

Anti-HIV monoclonal antibody VRC07-523LS safe and well-tolerated in phase I study

First phase II results for GV-1001 in benign prostatic hyperplasia

FDA approves Ilumya for moderate to severe plaque psoriasis